Free Trial

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

Enliven Therapeutics logo with Medical background
Remove Ads

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company's stock, valued at $265,330. This represents a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

  • On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
  • On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total value of $70,167.50.
  • On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
  • On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
  • On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Stock Down 2.1 %

NASDAQ:ELVN traded down $0.46 on Friday, reaching $21.00. 347,272 shares of the company's stock traded hands, compared to its average volume of 237,554. The firm has a market cap of $1.03 billion, a PE ratio of -11.05 and a beta of 1.04. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The stock has a 50-day simple moving average of $21.87 and a 200-day simple moving average of $23.90.

Remove Ads

Analyst Ratings Changes

Several research firms have issued reports on ELVN. Robert W. Baird boosted their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a report on Friday, November 15th. BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They set a "buy" rating and a $42.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $38.25.

View Our Latest Report on Enliven Therapeutics

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the business. FMR LLC increased its holdings in shares of Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after buying an additional 199,692 shares during the last quarter. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after acquiring an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. grew its position in Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after acquiring an additional 55,283 shares in the last quarter. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after acquiring an additional 290,153 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its position in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after purchasing an additional 135,969 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Featured Articles

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Should You Invest $1,000 in Enliven Therapeutics Right Now?

Before you consider Enliven Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.

While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

NVIDIA is falling closer to the $100 mark—could it drop even further? Analysts predict up to 50% upside; is this a buying opportunity or a warning sign?

Related Videos

Is There Still Money in AI? How to Invest in the Next Big Wave
3 AI Stocks to Watch After NVIDIA’s Dip
5 Stocks to BUY NOW in March 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads